Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome

Monozygotic twins, each of whom has breast cancer, offer a natural study population for gene‐environmental interactions as causation of cancer, because they are genetically identical. If heritable factors play a large role in the origin of a neoplasm, disease concordance should be significant in monozygotic twins. Two monozygotic triplet sisters carrying a germline BRCA1 gene mutation (5382insC) who both developed breast cancer at early ages were studied for loss of heterozygosity (LOH) in their microdissected, paraffin‐embedded tumors along with control blood and stromal breast tissue at 19 chromosomal arms using 161 microsatellite markers. Microdissected areas of normal lobular and ductal epithelium and ductal in situ carcinoma were also studied for LOH using a subset of microsatellite markers. The mother's DNA (extracted from peripheral blood lymphocytes) was analyzed to determine the parental allele under LOH in each case. Both tumors demonstrated similar histologic features suggestive of a secretory variant of ductal carcinoma. The tumors from both sisters had similar overall LOH frequency expressed by the fractional allelic loss (FAL) indices (0.56 vs. 0.60) and demonstrated concordance for loss or retention at 82 of 97 informative markers (85% correlation). In addition, detailed mapping analysis of several chromosomal arms revealed that identical breakpoints were detected in both tumors at several chromosome regions. Finally, in both sisters' tumors, when a chromosome exhibited allelic loss, all of the markers exhibited LOH of the same parental allele even when there were intervening regions of retention of heterozygosity. In contrast, 17 archival sporadic breast carcinomas demonstrated a wide range of FAL indexes and highly individual patterns of LOH. Our findings support the hypothesis that inherited factors play a role in the development of the multiple somatic deletions occurring in breast carcinomas. Whether one of these factors is the mutant BRCA1 allele or some other gene(s) remains to be determined. Genes Chromosomes Cancer 28:359–369, 2000. © 2000 Wiley‐Liss, Inc.

[1]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[2]  B. Gusterson,et al.  Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.

[3]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[4]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[5]  W. Liu,et al.  Allele-specific late replication and fragility of the most active common fragile site, FRA3B. , 1999, Human molecular genetics.

[6]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[7]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[8]  C. Rubin,et al.  Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions , 1998, Annals of Internal Medicine.

[9]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[10]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[11]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[12]  H R Garner,et al.  Computerized polymorphic marker identification: experimental validation and a predicted human polymorphism catalog. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Geradts,et al.  Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. , 1998, American journal of clinical pathology.

[14]  J. Minna,et al.  Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. , 1998, JAMA.

[15]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[16]  H. Huang,et al.  Common fragile sites and cancer (review). , 1998, International journal of oncology.

[17]  A. Swerdlow,et al.  Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology , 1997, The Lancet.

[18]  M. Lai,et al.  A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. , 1997, Cancer research.

[19]  J. Minna,et al.  Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. , 1997, Cancer research.

[20]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[21]  M Feychting,et al.  Cancer in twins: genetic and nongenetic familial risk factors. , 1997, Journal of the National Cancer Institute.

[22]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[23]  A. Hochberg,et al.  Relaxation of imprinting in carcinogenesis. , 1996, Cancer genetics and cytogenetics.

[24]  A. Berchuck,et al.  BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[26]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[27]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[28]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[29]  W. Recant,et al.  Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers , 1995, Genes, chromosomes & cancer.

[30]  M. Stratton,et al.  Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. , 1995, Journal of clinical pathology.

[31]  J. Minna,et al.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. , 1995, JAMA.

[32]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[33]  B. Ljung,et al.  Deletion of two separate regions on chromosome 3p in breast cancers. , 1994, Cancer research.

[34]  D. Page,et al.  Pathology and heredity of breast cancer in younger women. , 1994, Journal of the National Cancer Institute. Monographs.

[35]  M. Slattery,et al.  A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. , 1993, JAMA.

[36]  G. Merlo,et al.  Genetic and molecular heterogeneity of breast cancer cells. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[37]  A. Feinberg.  Genomic imprinting and gene activation in cancer , 1993, Nature Genetics.

[38]  Knudson Ag.  The ninth Gordon Hamilton-Fairley memorial lecture: Hereditary cancers: clues to mechanisms of carcinogenesis , 1989 .

[39]  A. Knudson,et al.  Hereditary cancers : clues to mechanisms of carcinogenesis , 2007 .

[40]  T. P. Dryja,et al.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma , 1983, Nature.